StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Lilly (LLY) and Incyte (INCY) Announces Additional Results from Pivotal RA-BEAM Study Published in NEJM
February 16, 2017 7:35 AM
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Next Articles
Jefferies Reiterates Buy Rating and $140 PT on Incyte Corp. (INCY); EU Bari Label In-Line
February 17, 2017 8:37 AM
Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal
February 15, 2017 5:57 PM
